<DOC>
	<DOCNO>NCT02204371</DOCNO>
	<brief_summary>This study investigate whether pazopanib reduce epistaxis improve anaemia subject hereditary haemorrhagic telangiectasia ( HHT ) dose well tolerate . The study 2 part . Part A open label , dose-escalation study 4 cohort approximately 6 subject receive increase dos pazopanib maximum 12 week . The dose first cohort 50mg per day maximum dose cohort 400 mg per day . Dose escalation occur plan predefined safety stop criterion meet least 4 subject cohort demonstrate efficacy ( measure epistaxis , haemoglobin , transfusion iron infusion requirement ) . If efficacy demonstrate Part A acceptable safety profile , Part B initiate define optimal dose ( ) include dose duration/schedule provide support proof mechanism . Approximately 15 subject participate randomise active placebo ratio 3:2 . This part study double-blind .</brief_summary>
	<brief_title>Evaluation Pazopanib Bleeding Subjects With Hereditary Haemorrhagic Telangiectasia</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<criteria>Males/females age 18 75 year age inclusive , time signing informed consent . Diagnosis definite possible HHT Curaçao criterion . According Curaçao criterion , definite diagnosis HHT define least 3 follow criterion possible diagnosis define 2 criterion : ) spontaneous recurrent epistaxis ; b ) multiple telangiectasias characteristic site : lip , oral cavity , finger , nose ; c ) visceral lesion : gastrointestinal ( GI ) telangiectasia , pulmonary , hepatic , cerebral spinal arteriovenous malformation ( AVMs ) ; ) first degree relative HHT accord criterion . Subject meet least one follow criterion : ) Severe epistaxis previous 4 week define average least 3 nose bleeds per week AND total duration great 15 min per week AND require iron therapy ( oral and/or intravenous ) ; b ) Moderate severe iron deficiency anaemia ( Hgb &lt; 11gram [ g ] /deciliter [ dL ] , screen ) despite iron infusion ( least 0.5g iron per month ) blood transfusion ( least 2 unit per month ) AND substantial compromise quality life accord investigator ( e.g . nose bleeds , lethargic , maintain job , listless , fatigue ) . Anaemia must HHT related opinion investigator , ie : due HHTdefined bleeding ( epistaxis and/or bleed GI tract [ presence telangiectatic lesion , exclusion active ulcer disease infection , inflammation ] ) , lack known etiology blood dyscrasia . Epistaxis ( applicable ) consider clinically stable 4 week prior Screening clinical judgment investigator ( i.e . major change frequency duration epistaxis ) . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhoea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( MIU/mL ) estradiol &lt; 40 picogram per milliliter ( pg/mL ) ( &lt; 147 picomole per liter [ pmol/L ] ) confirmatory ] . Capable give write informed consent , include compliance requirement restriction list consent form . Subject able willing return outpatient visit protocol specify interval . Subject agree undergo laser ablation nasal telangiectasias take experimental therapy HHT study drug participate study ( counter medication , topical treatment , nasal hygiene palliative therapy acceptable long use consistent ) . If subject stop take experimental therapy entry study washout period least 5 halflives prior start runin ) . Based average correct QT either Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) value triplicate ECGs obtain brief recording period : QTc &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ; exception vascular abnormality relate HHT ) . Subject know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib opinion investigator contradict participation . Currently untreated cerebral vascular malformation ( CVMs ) ( Note : magnetic resonance image [ MRI ] scan need repeat Screen CVMs absent scan age 18 year last 5 year ) . Currently know pulmonary AVMs feeding artery diameter &gt; 3 millimeter ( mm ) . Symptomatic liver AVMs ( define chronic right upper quadrant pain , symptomatic portal hypertension heart failure ) . Known significant bleeding source nasal gastrointestinal . Systemic use vascular endothelial growth factor ( VEGF ) inhibitor past 12 week previous enrolment study . Current use anticoagulant include limited vitamin K antagonist ( e.g. , warfarin ) dose ; unfractionated low molecular weight heparin standard dos treatment venous thromboembolism ( VTE ) ( e.g. , enoxaparin ) ; antiplatelets ( e.g. , clopidogrel ) , direct factor Xa inhibitor ( e.g. , apixaban ) . Use low dose aspirin &lt; = 81mg allow long use consistent . Active recent onset diarrhoea . Current recent malignancy ( except nonmelanoma skin cancer ) Subject : ) major surgery ( eg , surgical ligation AVM ) trauma within 28 day ; b ) minor surgical procedure ( eg , central venous access line removal ) within 7 day prior dose ; c ) nonhealing wound , fracture ulcer Subject clinically significant gastrointestinal abnormality ( HHTrelated vascular lesion ) include , limited : malabsorption syndrome , major resection stomach small bowel could affect absorption study drug ( eg , short bowel syndrome ) , active peptic ulcer , know intraluminal metastatic lesions/s suspect bleeding , inflammatory bowel disease , ulcerative colitis gastrointestinal condition increase risk perforation , lifetime history abdominal fistula , gastrointestinal perforation intraabdominal abscess Subject history cerebrovascular accident ( include transient ischaemic attack ) , pulmonary embolism untreated deep vein thrombosis ( DVT ) within 6 month prior first dose study drug . Subject history one follow cardiovascular condition within 6 month prior first dose study drug : cardiac angioplasty stenting , myocardial infarction , unstable angina , ischaemic stroke , symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Hgb &lt; 7 gram per deciliter ( g/dL ) . Platelets &lt; 100x10^9/L , International normalize ratio ( INR ) &gt; 1.2x upper limit normal ( ULN ) activate partial thromboplastin time ( aPTT ) &gt; 1.2xULN . Alanine aminotransferase ( ALT ) &gt; = 2xULN bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Subject poorly control hypertension [ define systolic blood pressure ( SBP ) &gt; = 140 millimeter mercury ( mmHg ) diastolic blood pressure ( DBP ) &gt; = 90mmHg ] . Initiation adjustment antihypertensive medication ( ) permit prior study entry . At Screening , blood pressure must assess three time mean SBP/DBP must &lt; 140/90 mmHg order subject eligible study . Substantive renal disease ( estimate glomerular filtration rate [ eGFR ] &lt; 60 mL/minute/1.73 meter^3 calculate use CockcroftGault formula ) Thyroid stimulate hormone &gt; ULN . Urine protein creatinine ratio &gt; 0.3 White blood cell count &lt; 3500/mm^3 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior start runin period : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Unable unwilling discontinue use prohibit medication mention least 14 day 5 halflives drug ( whichever longer ) prior start runin period duration study . Medications inhibit Cytochrome P450 3A4 ( CYP3A4 ) may result increase plasma pazopanib concentration ; therefore , coadministration strong CYP3A4 inhibitor PROHIBITED begin 14 day prior first dose study treatment 15 day last dose pazopanib . Strong CYP3A4 inhibitor include ( limited ) : Antibiotics : clarithromycin , telithromycin , troleandomycin ; human immunodeficiency virus ( HIV ) : protease inhibitor ( ritonavir , indinavir , saquinavir , nelfinavir , amprenavir , lopinavir ) ; Antifungals : itraconazole , ketoconazole , voriconazole , fluconazole ; Antidepressants : nefazodone , Miscellaneous : grapefruit , grapefruit juice grapefruit product . statin , anticoagulant tamoxifen use prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>hereditary haemorrhagic telangiectasia</keyword>
	<keyword>bleeding</keyword>
</DOC>